Johnson and Johnson On Tuesday, an estimated revenue of between $ 3 billion and $ 3.5 billion from its Covid-19 vaccine this year, compared to the $ 2.39 billion it generated in 2021, is a sign that the drugmaker is facing fewer manufacturing problems and a increase in demand.
Delivery delays and inequality in demand last year prevented J&J from achieving its goal of raising $ 2.5 billion in revenue from the Covid-19 vaccine in 2021.
Shares of the company fell 1.2% before the opening session in Wall street, as the pharmaceutical company’s total turnover was also below market forecasts.
J & J’s single-dose Covid-19 injection, once thought to be an important tool for vaccinating people living in hard-to-reach areas, has fallen behind schedule in the United States and Europe.
The drugmaker experienced quality problems at a manufacturing plant in Baltimore last year, which led to the disposal of millions of doses.
Contributions from the coronavirus vaccine makes up a small portion of J & J’s overall sales, as the company sells them at a non-profit price.
Opponents of Pfizer, however, benefited from the sales of their vaccines, predicting multimillion-dollar revenue from their injections in 2021 and 2022.
J & J’s prediction comes at a time when he wants to separate his health unit from the consumer and focus on the medical device and pharmaceutical businesses.
Sales of cancer drug Imbruvica, from J&J and AbbVie, totaled $ 1.06 billion, below Wall Street estimates of $ 1.17 billion. Stelara sales, which reached $ 2.33 billion, also missed revenue estimates of $ 2.45 billion.
Overall, J & J’s revenue stood at $ 24.8 billion, according to estimates by analysts polled by Refinitiv.
Reference-www.eleconomista.com.mx